Search Results

Website profile

Firstword Pharma

firstwordpharma.com

All articles Clear site filter

FirstWord

112articles · 30d
14+ hour agolatest article
Aug 17, 2026earliest in window
0%with images
13avg words

articles per day

People

Places

Organizations

Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

FirstWord Pharma
firstwordpharma.com > story > 7984983

WCLC26: GSK's ris-rez cuts death risk 54% in China Phase III lung cancer trial

21+ hour, 47+ min ago (16+ words) FirstWord Pharma...

firstwordpharma.com
firstwordpharma.com > story > 7973027

Friday Five??? Novartis' stumbles spark boardroom backlash, Nodthera name drops, FDA throws wrench into Biohaven deal???and more

3+ day, 12+ hour ago (19+ words) Friday Five – Novartis' stumbles spark boardroom backlash, Nodthera name drops, FDA throws wrench into Biohaven deal…and more firstwordpharma.com...

FirstWord PHARMA
firstwordpharma.com > story > 7972962

Install

Firstword Pharma

Please confirm you are human

News

WCLC26: GSK's ris-rez cuts death risk 54% in China Phase III lung cancer trial

Friday Five??? Novartis' stumbles spark boardroom backlash, Nodthera name drops, FDA throws wrench into Biohaven deal???and more

AbbVie aims to expand Qulipta's label into new migraine market

Takeda's R&D head Andy Plump to retire after back-to-back approvals

NodThera rebrands as Rezera, charts registrational path for PAD drug

Encoded pulls in $275M for pivotal study of Dravet gene therapy

Beeline buzzes ahead to pivotal lupus trials after mid-stage success

Solstice raises $225M to advance next-gen CTLA-4 immunotherapy

Physician Views Preview: How are prescribing patterns changing in COPD?

AI analysis from Brainomix adds to evidence backing Endeavor's IPF therapy